ClinicalTrials.gg
CompletedNCT05795517Updated Apr 9, 2024

Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)

A Phase 2 interventional study of HSK31679 low dose and HSK31679 medium dose in Hypercholesterolemia, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
25th of 53
210 · median 207
Started
2023
with 8 others
Phase 2
6 of 59
none open now
Registered
41st of 59
by date

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 25th largest by enrollment of the 53 interventional ones that give a count, is one of 9 that started in 2023, is one of 6 in phase 2, and was the 41st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12 weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD).

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • hypercholesterolemia
  • non-alcoholic fatty liver disease(NAFLD)
  • THR-β
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be willing to participate in the study and provide written .
  2. Male or female aged 18 ≤ age \< 65 at the time of signing the informed consent.
  3. At the time of screening, patients who had not received lipid-regulation therapy within 6 weeks had fasting LDL-C≥3.34mmol/L(130mg/dL).
  4. () ≥18kg/m2 and female subjects ≥45.0 kg and male subjects ≥50.0 kg.
  5. During screening, fasting triglyceride (TG) \<5.65 mmol/L.
  6. During screening,MRI-PDFF≥8%.
  7. Weight changes≤5% in the 4 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Did not discontinue any lipid-regulating therapy or any drug or supplement that may affect lipid levels 6 weeks before randomization or is expected to do so during the study period.
  2. Homozygous familial hypercholesterolemia (HoFH) was diagnosed by genetic or clinical criteria.
  3. Dyslipidemia caused by other diseases or drugs, such as rheumatoid arthritis, nephrotic syndrome, Cushing's syndrome, hypothyroidism, renal failure, systemic lupus erythematosus, glycogen accumulation, myeloma, lipodystrophy, acute porphyria, polycystic ovarian syndrome, etc
  4. Before screening, LDL-C plasma exchange was performed within 12 months.
  5. In the past, PCSK9 inhibitors, Lomitapide and Mipomersen were used for treatment.
  6. uncontrolled hypertension had systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg at screening/baseline.
  7. type 1 diabetes, or newly diagnosed type 2 diabetes within 1 month, or poorly controlled type 2 diabetes, or who could not maintain the same hypoglycemic regimen during the study.
  8. Stroke or (TIA), acute coronary syndrome, stable angina attack, severe deep vein thrombosis, or pulmonary embolism occurred in the 12 months prior to screening.
  9. Major surgery (including but not limited to: coronary or other revascularization, coronary artery bypass surgery, and transplantation) within 12 months prior to screening or planned during the study period.
  10. Chronic systemic disease or history, including but not limited to

    1. Have a serious cardiopulmonary disease or history,Neurological disease or history, disease,Chronic digestive disease or history
    2. Have thyroid disease or symptomatic abnormalities in thyroid function tests (e.g., thyroid stimulating hormone (TSH) \< 1.0 x lower limit of normal (LLN) or > 1.5 x (ULN))
    3. History of (excluding cured basal cell carcinoma of the skin, carcinoma in situ, and papillary thyroid carcinoma) or history of antitumor therapy within 5 years prior to screening
    4. Disease or medical history assessed by the investigator as likely to affect the study
  11. Bariatric surgery within 12 months at the time of screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    HSK31679 low dose

    Drug: HSK31679 low dose

  • Experimental
    HSK31679 medium dose

    Drug: HSK31679 medium dose

  • Experimental
    HSK31679 high dose

    Drug: HSK31679 high dose

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Ezetimibe

    Drug: Ezetimibe 10mg

Interventions

  • HSK31679 low dose and placebo of HSK31679 ,QD,oral,Day1 to week 12

  • HSK31679 medium dose and placebo of HSK31679 ,QD,oral,Day1 to week 12

  • HSK31679 high dose and placebo of HSK31679 ,QD,oral,Day1 to week 12

  • DrugPlacebo

    placebo ,QD,oral,Day1 to week 12

  • Ezetimibe 10mg+placebo of HSK31679 ,QD,oral,Day1 to week 12

06

What researchers measure

Primary outcomes

  1. Percentage change in LDL-C from baseline at 12 week;

    Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 12 weeks of treatment;

    Time frame: Baseline and Week 12

  2. Percentage change in MRI-PDFF from baseline at 12 week;

    Percentage change of MRI-PDFF(change in liver fat content by nuclear magnetic resonance - Proton Density Fat Fraction) from baseline after 12 weeks of treatment;

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Percentage change in fasting LDL-C from baseline;

    Percentage change in fasting low-density lipoprotein cholesterol (LDL-C) from baseline after 2, 4, and 8 weeks of treatment;

    Time frame: Week2,4,8

  2. The proportion of patients with MRI-PDFF decreased by > 30%

    After 12 weeks of treatment, the proportion of patients with MRI-PDFF decreased by \> 30%;

    Time frame: Baseline and Week 12

  3. Proportion of patients with LDL-C<3.34mmol/L(<130mg/dL)

    After 12 weeks of treatment, the proportion of patients with LDL-C\<3.34mmol/L(\<130mg/dL)

    Time frame: Baseline and Week 12

  4. Percentage change of fasting TG from baseline;

    After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting triglycerides (TG), from baseline;

    Time frame: Week2,4,8,12

  5. Percentage change of fasting TC from baseline;

    After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting total cholesterol (TC) from baseline;

    Time frame: Week2,4,8,12

  6. Percentage change of fasting HDL-C from baseline;

    After 2, 4, 8, 12 weeks of treatment, Percentage change of fasting high-density lipoprotein cholesterol (HDL-C) from baseline;

    Time frame: Week2,4,8,12

  7. Percentage change in body weight from baseline

    Percentage change in body weight from baseline after 12 weeks of treatment.

    Time frame: Baseline and Week 12

  8. AUC0-τ of HSK31679 (All subjects)

    Time frame: up to 2,4,7 weeks

  9. Cmax of HSK31679 (All subjects)

    Time frame: up to 2,4,7 weeks

07

Study locations

1 site
  • Beijing Tsinghua Changgung Hospital, Tsinghua University
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Feb 2024, 9 months.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 9 months is close to that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
Apr 3, 2023
StartActual
Apr 26, 2023
Primary completionActual
Feb 20, 2024
CompletionActual
Mar 1, 2024
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05795517
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Apr 26, 2023
Primary completion
Feb 20, 2024
Completion
Mar 1, 2024
Last update
Apr 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK31679

Start the discussion